Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The class action pertains to investors who purchased Telix securities between February 21, 2025, and August 28, 2025, and they may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - A lead plaintiff must be appointed by January 9, 2026, to represent other class members in directing the litigation [3][6]. Group 2: Allegations Against Telix Pharmaceuticals - The lawsuit alleges that during the class period, defendants made materially false and misleading statements regarding the progress of Telix's prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. - As a result of these misstatements, the defendants' claims about Telix's business operations and prospects were deemed materially false and misleading, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].